Investor Presentaiton

LOVAVO US De ADVERSE EVENT SUMMARY PraB ES 40U N=51 OnaB 20U N=50 PraB 20U N=53 SEVERITY OF ADVERSE EVENTS MILD 7 (87.5%) 9 (75.0%) 16 (100%) JEUVEAU EXTRA-STRENGTH PHASE II DURATION STUDY SAFETY ADVERSE EVENTS EV • MODERATE 1 (12.5%) 3 (25.0%) 0 (0%) SEVERE SERIOUS Adverse Event Severity Number of AE's 36 events Mild: 88.9% Moderate: 11.1% Severe: 0% Serious AE: None 0 0 0 0 0 20 20

View entire presentation